Gilead Sciences Inc. (GILD): Price and Financial Metrics

Gilead Sciences Inc. (GILD): $71.61

0.28 (+0.39%)

POWR Rating

Component Grades













Add GILD to Watchlist
Sign Up

Industry: Biotech


of 506

in industry


  • Value is the dimension where GILD ranks best; there it ranks ahead of 98.84% of US stocks.
  • GILD's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
  • GILD ranks lowest in Momentum; there it ranks in the 4th percentile.

GILD Stock Summary

  • GILD has a market capitalization of $89,434,227,355 -- more than approximately 97.16% of US stocks.
  • With a one year PEG ratio of 1.03, Gilead Sciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 5.6% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Gilead Sciences Inc is reporting a growth rate of 1,688.48%; that's higher than 98.63% of US stocks.
  • Stocks that are quantitatively similar to GILD, based on their financial statements, market capitalization, and price volatility, are EW, ADI, AMGN, ATVI, and NTES.
  • Visit GILD's SEC page to see the company's official filings. To visit the company's web site, go to

GILD Valuation Summary

  • GILD's price/sales ratio is 3.4; this is 10.53% lower than that of the median Healthcare stock.
  • GILD's price/sales ratio has moved down 24.1 over the prior 243 months.
  • Over the past 243 months, GILD's price/sales ratio has gone down 24.1.

Below are key valuation metrics over time for GILD.

Stock Date P/S P/B P/E EV/EBIT
GILD 2021-08-31 3.4 4.6 17.7 15.0
GILD 2021-08-30 3.4 4.6 17.5 14.9
GILD 2021-08-27 3.4 4.5 17.3 14.8
GILD 2021-08-26 3.4 4.5 17.3 14.8
GILD 2021-08-25 3.4 4.5 17.3 14.8
GILD 2021-08-24 3.4 4.6 17.5 14.9

GILD Growth Metrics

  • The 3 year net cashflow from operations growth rate now stands at -59.15%.
  • The 4 year net income to common stockholders growth rate now stands at -71.39%.
  • Its year over year net cashflow from operations growth rate is now at 2.25%.
GILD's revenue has moved down $2,463,000,000 over the prior 52 months.

The table below shows GILD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 26,638 9,092 5,162
2021-03-31 25,564 9,342 301
2020-12-31 24,689 8,168 123
2020-09-30 23,147 8,832 1,268
2020-06-30 22,174 9,481 -257
2020-03-31 22,716 9,136 4,962

GILD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GILD has a Quality Grade of B, ranking ahead of 84.92% of graded US stocks.
  • GILD's asset turnover comes in at 0.402 -- ranking 114th of 677 Pharmaceutical Products stocks.
  • HTBX, PTE, and DRNA are the stocks whose asset turnover ratios are most correlated with GILD.

The table below shows GILD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.402 0.801 0.179
2021-03-31 0.405 0.806 0.066
2020-12-31 0.403 0.815 0.058
2020-09-30 0.389 0.790 0.058
2020-06-30 0.375 0.786 0.009
2020-03-31 0.373 0.794 0.123

GILD Price Target

For more insight on analysts targets of GILD, see our GILD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.99 Average Broker Recommendation 1.68 (Moderate Buy)

GILD Stock Price Chart Interactive Chart >

Price chart for GILD

GILD Price/Volume Stats

Current price $71.61 52-week high $73.34
Prev. close $71.33 52-week low $56.56
Day low $70.44 Volume 10,888,300
Day high $71.76 Avg. volume 7,349,103
50-day MA $70.30 Dividend yield 3.97%
200-day MA $66.20 Market Cap 89.79B

Gilead Sciences Inc. (GILD) Company Bio

Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. Daniel O’Day has been Gilead Science’s Chief Executive Officer since March of 2019 and the company is headquartered in Foster City, California. With over 10,000 employees worldwide, the company has operations in North America, Asia, the Middle East and Europe. As of 2019, the company had global sales of $22.1 billion. Some of Gilead Science’s major competitors are Novo Nordisk A/S ADR (NVO), Biogen Inc. (BIIB), and Novartis AG ADR (NVS).

GILD Latest News Stream

Event/Time News Detail
Loading, please wait...

GILD Latest Social Stream

Loading social stream, please wait...

View Full GILD Social Stream

Latest GILD News From Around the Web

Below are the latest news stories about Gilead Sciences Inc that investors may wish to consider to help them evaluate GILD as an investment opportunity.

FDA advisory panel authorizes booster dose for those 65 & older

Yahoo Finance’s Anjalee Khemlani reports the FDA advisory panels' second vote regarding Covid-19 boosters. 

Yahoo | September 17, 2021

FDA advisory panel votes against approving COVID-19 booster

Yahoo Finance’s Anjalee Khemlani reports the latest on the FDA’s decision regarding covid booster shots.

Yahoo | September 17, 2021

Wearing masks is something we should consider possibly in every flu, winter season: Doctor

Dr. Hiral Tipirneni, Emergency Medicine Physician, joins Yahoo Finance Live to discuss the latest on the coronavirus pandemic.

Yahoo | September 17, 2021

Doctor: This conversation about boosters doesn’t take place just in the U.S.

Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.

Yahoo | September 17, 2021

Gilead Churns Out Additional Trodelvy Data

Gilead Sciences Inc (NASDAQ: GILD) announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies. The results were presented at the European Society of Medical Oncology (ESMO21) Congress 2021. The Company said that a sub-analysis from the study showed significant and clinically meaningful improvements in health-related quality of life over the st

Yahoo | September 16, 2021

Read More 'GILD' Stories Here

GILD Price Returns

1-mo -0.15%
3-mo 7.40%
6-mo 13.31%
1-year 14.92%
3-year 7.65%
5-year 4.38%
YTD 26.88%
2020 -6.70%
2019 7.88%
2018 -9.92%
2017 2.96%
2016 -27.59%

GILD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GILD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1505 seconds.